BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dijk W, Le May C, Cariou B. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism? Trends Endocrinol Metab 2018;29:420-34. [PMID: 29665987 DOI: 10.1016/j.tem.2018.03.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Suica VI, Uyy E, Ivan L, Boteanu RM, Cerveanu-hogas A, Hansen R, Antohe F. Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy. IJMS 2022;23:11174. [DOI: 10.3390/ijms231911174] [Reference Citation Analysis]
2 Waldmann E, Wu L, Busygina K, Altenhofer J, Henze K, Folwaczny A, Parhofer KG. Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia). PLoS One 2022;17:e0265838. [PMID: 35320320 DOI: 10.1371/journal.pone.0265838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Vicente-Valor J, García-González X, Ibáñez-García S, Durán-García ME, de Lorenzo-Pinto A, Rodríguez-González C, Méndez-Fernández I, Percovich-Hualpa JC, Herranz-Alonso A, Sanjurjo-Sáez M. PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort. Biomed Pharmacother 2021;146:112519. [PMID: 34968928 DOI: 10.1016/j.biopha.2021.112519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xie M, Yu X, Chu X, Xie H, Zhou J, Zhao J, Su C. Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non‐small cell lung cancer. Thoracic Cancer. [DOI: 10.1111/1759-7714.14259] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Banerjee Y, Pantea Stoian A, Cicero AFG, Fogacci F, Nikolic D, Sachinidis A, Rizvi AA, Janez A, Rizzo M. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin Drug Saf 2021;:1-12. [PMID: 34596005 DOI: 10.1080/14740338.2022.1988568] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
6 Matías-Pérez D, Pérez-Santiago AD, Sánchez Medina MA, Alpuche Osorno JJ, García-Montalvo IA. PCSK9 Gene Participates in the Development of Primary Dyslipidemias. Balkan J Med Genet 2021;24:5-14. [PMID: 34447653 DOI: 10.2478/bjmg-2021-0009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Macchi C, Ferri N, Sirtori CR, Corsini A, Banach M, Ruscica M. Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact. Am J Pathol 2021;191:1385-97. [PMID: 34019847 DOI: 10.1016/j.ajpath.2021.04.016] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 32.0] [Reference Citation Analysis]
8 Fischer LT, Hochfellner DA, Knoll L, Pöttler T, Mader JK, Aberer F. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus. Cardiovasc Diabetol 2021;20:89. [PMID: 33894772 DOI: 10.1186/s12933-021-01283-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Andreadou I, Tsoumani M, Vilahur G, Ikonomidis I, Badimon L, Varga ZV, Ferdinandy P, Schulz R. PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation. Front Physiol 2020;11:602497. [PMID: 33262707 DOI: 10.3389/fphys.2020.602497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
10 Zhao Q, Zhang TY, Cheng YJ, Ma Y, Xu YK, Yang JQ, Zhou YJ. Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status: an observational cohort study from China. Lipids Health Dis 2020;19:179. [PMID: 32736631 DOI: 10.1186/s12944-020-01355-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Garçon D, Moreau F, Ayer A, Dijk W, Prieur X, Arnaud L, Roubtsova A, Seidah N, Prat A, Cariou B, Le May C. Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice. Arterioscler Thromb Vasc Biol 2020;40:2084-94. [PMID: 32673528 DOI: 10.1161/ATVBAHA.120.314194] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
12 Molina-Vega M, Castellano-Castillo D, Sánchez-Alcoholado L, Plaza-Andrade I, Perera-Martin G, Cabrera-Mulero A, Fernández-García JC, Ramos-Molina B, Cardona F, Tinahones FJ. Relationship of Zonulin with Serum PCSK9 Levels after a High Fat Load in a Population of Obese Subjects. Biomolecules 2020;10:E748. [PMID: 32403394 DOI: 10.3390/biom10050748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhang X, Stiekema LCA, Stroes ESG, Groen AK. Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a). Lipids Health Dis 2020;19:91. [PMID: 32393252 DOI: 10.1186/s12944-020-01280-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, Domenger C, Letierce A, Israel M, Samuel R, Del Prato S. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovasc Diabetol 2020;19:14. [PMID: 32035487 DOI: 10.1186/s12933-020-0991-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
15 Warden BA, Fazio S, Shapiro MD. The PCSK9 revolution: Current status, controversies, and future directions. Trends Cardiovasc Med 2020;30:179-85. [PMID: 31151804 DOI: 10.1016/j.tcm.2019.05.007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 14.7] [Reference Citation Analysis]
16 Dijk W, Cariou B. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia. Diabetes Obes Metab 2019;21:39-51. [DOI: 10.1111/dom.13636] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Dijk W, Le May C, Cariou B. Efficacité et sécurité des inhibiteurs de PCSK9 dans le diabète. Médecine des Maladies Métaboliques 2019;13:147-155. [DOI: 10.1016/s1957-2557(19)30044-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Bojanin D, Vekic J, Milenkovic T, Vukovic R, Zeljkovic A, Stefanovic A, Janac J, Ivanisevic J, Mitrovic K, Miljkovic M, Spasojevic-kalimanovska V. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control. Atherosclerosis 2019;280:14-20. [DOI: 10.1016/j.atherosclerosis.2018.11.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
19 Macchi C, Ferri N, Favero C, Cantone L, Vigna L, Pesatori AC, Lupo MG, Sirtori CR, Corsini A, Bollati V, Ruscica M. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals. Eur J Prev Cardiolog 2019;26:578-88. [DOI: 10.1177/2047487318815320] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
20 Wargny M, Ducluzeau P, Petit J, Le May C, Smati S, Arnaud L, Pichelin M, Bouillet B, Lannes A, Blanchet O, Lefebvre P, Francque S, Van Gaal L, Staels B, Vergès B, Boursier J, Cariou B. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. Atherosclerosis 2018;278:82-90. [DOI: 10.1016/j.atherosclerosis.2018.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
21 Santos HO, Bueno AA, Mota JF. The effect of artichoke on lipid profile: A review of possible mechanisms of action. Pharmacol Res 2018;137:170-8. [PMID: 30308247 DOI: 10.1016/j.phrs.2018.10.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
22 Drouin-Chartier JP, Tremblay AJ, Hogue JC, Lemelin V, Lamarche B, Couture P. Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance. J Lipid Res 2018;59:1501-9. [PMID: 29946054 DOI: 10.1194/jlr.M086264] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]